期刊文献+

一种β,β,β-二氟碘-1-苯基乙醇类化合物的简便合成方法

A Convenient Synthesis of β,β-Difluoro-β-iodo-1-phenylethan-1-ols
原文传递
导出
摘要 以二氟碘代丙酮类化合物为原料,利用硼氢化钠选择性还原得到高产率的二氟碘代醇类化合物.该合成方法具有反应条件温和,操作简单,产率高等特点,为合成更多的二氟取代醇类化合物试剂提供了简便的途径. The synthesis of α,α,α-iodo-difluoromethyl alcohols via the high selective reduction of iododifluoromethyl ketones by NaBH4 in methanol at 0 ℃ was reported. The reaction has some advantages, such as mild condition, simple synthetic route, and high yield. A convenient way to synthesize more difluoromethylation agents was provided.
作者 黄国志 任洁 郑笑笑 吴范宏 吴晶晶 Huang Guozhi;Ren Jie;Zheng Xiaoxiao;Wu Fanhong;Wu Jingjing(School of Chemical and Environmental Engineering,Shanghai Institute of Technologyy Shanghai 201418)
出处 《有机化学》 SCIE CAS CSCD 北大核心 2019年第12期3475-3482,共8页 Chinese Journal of Organic Chemistry
基金 国家自然科学基金面上(No.21672151)资助项目~~
关键词 二氟碘代苯乙酮 硼氢化钠 二氟碘代苯乙醇 选择性还原 iodo-difluoromethyl ketones NaBH4 iodo-difluoromethyl alcohol selective reduction
  • 相关文献

参考文献1

二级参考文献10

  • 1BAGCGHI S. Pembrolizumab for treatment of refractory melano-ma [J] . Lancet Oncol ,2014,15(10) :e419.
  • 2NAGORSEN D, KUFER P, BAEUERLE PA, et al. Blinatu-momab : a historical perspective [ J ] . Pharmacol Ther, 2012,136(3) :334 -342.
  • 3MARKHAM A, Idelalisib : first global approval [ J ] . Drugs ,2014,74( 14) : 1701 - 1707.
  • 4COOPER MR, CHIM H, CHAN H, et al Ceritinib: a new tyro-sine kinase inhibitor for NSCLC [ J ]. Ann Pharmacother, 2015,49(1) : 107-112.
  • 5JOHNSA JD,NEVILLE MW. Tasimelteon: a melatonin receptoragonist for non-24-hour sleep-wake disorder [ J ] . Ann Pharmaco-f/ier,2014,48(12) :1636 -1641.
  • 6HAUSER RA, ISAACSON S’ USK JP,^ al. Droxidopa for theShort-Term Treatment of Symptomatic Neurogenic Orthostatic Hy-potension in Parkinson's Disease ( nOH306B) [ J ]. Mov Disord,2014,doi: 10. 1002/mds. 26086.
  • 7U.S. FDA approves Merck blood clot preventer[ EB/OL]. (2014 -05 - 09) [2015 - 01 -06]. http://cn.reuters.com/article/com-panyNewsEng/iaCNL2NONU2I120140508.
  • 8SYLVANT? (siltuximab) Receives FDA Approval to Treat Mul-ticentric Castleman's Disease ( MCD) [ EB/OL]. ( 2014 - 04 -23 ) [2015-01 - 06 ] . http://www. pmewswire. com/news-re-leases/ sylvant-siltuximab-receives-fda-approval-to-treat-multicen-tric-castlemans-disease-mcd-256428511. html.
  • 9SCHWEIGHARDT B, TOMPKINS T, LAU K,et al. Immunoge-nicity of elosulfase alfa, an enzyme replacement therapy in pa-tients with morquio a syndrome : results from MOR-004 , a phaseIII trial [ J ]. Clin Ther,2GU, pii : S0149-2918 ( 14 ) 00741-3.doi: 10. 1016/j. clinthera. 2014. 11.005.
  • 10GARCIA BUSTOS MF, BARRIO A, PARODI C,et al. Milte-fosine versus meglumineantimoniate in the treatment of mucosalleishmaniasis[ J]. Medicina (B Aires) , 2014,74(5):371 -377.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部